Key Milestones
2011
Promontory Therapeutics was founded (under the name Phosplatin Therapeutics) with seed funding and its discovery-stage license transaction with Ohio University for a family of compounds intended for development as anti-cancer agents.
2014
Promontory launched its First-in-Human Phase I Clinical Trial of PT-112 in Solid Tumors.
2018
PT-112 received FDA Orphan Drug Designation for use in thymoma and thymic carcinoma.
The PT-112-101 Phase I study team was awarded with “Best Poster” honors across the full Developmental Therapeutics category at the European Society of Medical Oncology Annual Congress in Munich, Germany.
2019
Promontory gathered experts during the European Society of Medical Oncology Annual Congress to constitute its Clinical Advisory Group in prostate cancer.
Promontory also presented at BIO CEO.
2020
Positive data from two phase I studies in metastatic castrate-resistant prostate cancer (mCRPC) patients were presented at the American Society of Cancer Oncology’s Genitourinary (ASCO GU) Symposium.
Promontory announced the publication in OncoImmunology of in vitro and in vivo data demonstrating PT-112’s induction of immunogenic cell death (ICD).
The Phase 2 study of PT-112 in mCRPC was launched late in the year, amidst the global Covid-19 pandemic.
Promontory Therapeutics CEO Robert Fallon sat down with Proactive's Christine Corrado at the BIO CEO & Investor Conference in New York.
2022
Promontory Therapeutics received the 2022 “Cancer Immunology Solution of the Year” award in the second annual BioTech Breakthrough Awards program. The Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry.
2023
Promontory Therapeutics was named a Best Startup Nominee under the prestigious Prix Galien.
The PT-112 Phase 2 study in mCRPC was expanded into France, led by the Gustave Roussy Paris, and became the first international member of the Paris Saclay Cancer Cluster.
At the Sachs 9th Annual Immuno-Oncology Innovation Forum, Promontory Therapeutics’ Chief Medical Officer, Johan Baeck, presented on clinical progress with lead therapeutic candidate, PT-112.
Promontory Therapeutics CMO, Johan Baeck, MD, speaks at Sachs I-O Innovation Forum on June 2, 2023.
